SecBot SecBot
Insider Cluster (8 insiders) ·Filed May 1, 2026

TVTX

Travere Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago
Insider cluster: 2 insiders, $1.3M total
Actionable Insight ▼ Bearish

The convertible offering overhang and insider selling after a strong earnings beat suggest near-term downside pressure. Monitor the final pricing and conversion terms of the notes. The stock's strong quarter could provide a floor, but dilution risk may cap upside. Consider hedging against potential volatility through options strategies.

DirectionBearish
Confidencemedium
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$44.12
T+0 close · Apr 30, 2026 · via day close
Latest settled
+26.72%
T+60 · $55.91
Vs SPY
+23.65%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $44.12entry
  2. T+1 · 7mo ago +1.79%α +2.13% · $44.91
  3. T+5 · 6mo ago −3.31%α −5.66% · $42.66
  4. T+20 · 6mo ago +2.09%α −3.20% · $45.04
  5. T+60 · 4mo ago +26.72%α +23.65% · $55.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Multiple Travere Therapeutics insiders, including the CEO, CFO, and CMO, sold shares in the days following strong Q1 2026 earnings and a $400M convertible note offering. Total open-market sales of $2.74M are tiny relative to the $4.1B market cap, but the clustering of sales by top executives after a dilutive capital raise raises governance concerns. The offering represents ~10% dilution, partially offset by robust revenue growth.

Key Financial Metrics

Direction
selling
Total Value
$2.7M
Insiders
8

Key Facts

  • CEO Eric Dube sold $989K worth of shares on May 6 at $43.95.
  • CMO Jula Inrig sold $900K on May 4 and $101K on May 5, total $1.0M.
  • Total insider open-market sales in the cluster: ~$2.74M (0.07% of market cap).
  • Company filed a $400M convertible senior notes offering (424B5) on May 5, representing ~10% of market cap.
  • Q1 2026 revenue surged 88% YoY to $124.5M, driven by FILSPARI sales; net loss narrowed to $37.1M from $41.2M.
  • FDA approved FILSPARI for FSGS in April 2026, expanding addressable U.S. population to >100,000 patients.

Financial Impact

$400M convertible note offering (dilutive upon conversion); insider sales aggregated $2.74M

equity dilutioncash balanceshare count

Risk Factors

  • Dilution from $400M convertible notes; potential for share price to trade below conversion price.
  • Insider selling pattern may signal lack of confidence at current valuation, despite strong operational results.
  • Execution risk for FSGS launch and ongoing clinical trials (HARMONY study topline expected 2H 2027).

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TVTX-1778112057295

Track record

21 reports on TVTX

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +56.24% at T+60 after the Jun 2, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
  3. Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
  4. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
  5. Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
  6. Jul 9, 202618w ago 8-K Neutral 2/10 Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
  7. Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
  8. Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
  9. Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
  10. Jun 2, 202623w ago 8-K Bullish 6/10 Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 8h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026